Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DRONABINOL vs CESAMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at cannabinoid receptors CB1 and CB2; mimics endogenous cannabinoids, inhibiting adenylate cyclase and modulating neurotransmitter release (e.g., GABA, glutamate).
Nabilone is a synthetic cannabinoid (CB1 receptor agonist) with antiemetic and anxiolytic effects. It binds to central cannabinoid receptors (CB1) in the brain, inhibiting neurotransmitter release and modulating emetic pathways.
Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond to conventional antiemetics,Anorexia associated with weight loss in patients with AIDS
Prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) refractory to conventional antiemetics
2.5-10 mg orally twice daily, titrated to effect; maximum 15 mg per day in divided doses.
1-2 mg orally twice daily; maximum 6 mg/day.
Terminal elimination half-life is approximately 25–36 hours in chronic users due to extensive tissue distribution and slow release from fat stores; in naive users, half-life is shorter, around 20–30 hours. The prolonged half-life contributes to accumulation with repeated dosing.
Terminal elimination half-life is approximately 35 hours (range 25–50 hours) in adults. Due to prolonged half-life and active metabolites, steady-state may take 5–7 days; accumulation occurs with repeated dosing.
Hepatic via CYP2C9 and CYP3A4; major metabolite 11-hydroxy-dronabinol (active); further oxidation to 11-nor-9-carboxy-dronabinol.
Hepatic, primarily via CYP3A4 and CYP2C9; undergoes first-pass metabolism; multiple metabolites including active 11-hydroxy-nabilone
Primarily hepatic metabolism followed by biliary and fecal excretion. Approximately 65% eliminated in feces and 35% in urine, mostly as metabolites. Less than 5% of unchanged drug is excreted in urine.
Primarily hepatic metabolism with biliary excretion. ~65% eliminated in feces as metabolites, ~20% in urine. Less than 1% excreted unchanged.
Highly protein-bound: >95% bound primarily to albumin and, to a lesser extent, lipoproteins.
90–95% bound to plasma proteins, primarily albumin.
Extremely large, estimated at 10–30 L/kg due to high lipophilicity and extensive tissue uptake, particularly into adipose tissue and brain. This accounts for the slow elimination and prolonged action.
Approximately 2.5–5.5 L/kg, indicating extensive tissue distribution.
Oral bioavailability is low and variable, approximately 10–20% due to extensive first-pass hepatic metabolism. There is significant interindividual variability based on metabolism and formulation.
Oral bioavailability is approximately 10–20% due to extensive first-pass metabolism.
No dosage adjustment necessary for GFR >30 m L/min; insufficient data for GFR <30 m L/min, use with caution.
No specific dosage adjustment recommended based on GFR; use with caution in severe renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce starting dose to 1.25-2.5 mg twice daily and titrate cautiously; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Not recommended for use in children under 18 years due to lack of safety and efficacy data.
Not approved for use in pediatric patients; safety and efficacy not established.
Initiate at 1.25-2.5 mg twice daily; monitor for CNS effects and falls; titrate slowly.
Start at 1 mg once daily; titrate slowly due to increased sensitivity to adverse effects.
None
None
Central nervous system depression (e.g., dizziness, drowsiness, impaired coordination),Paradoxical reactions (e.g., increased nausea, vomiting),Risk of abuse and dependence due to psychoactive effects,Cardiovascular effects (e.g., tachycardia, hypotension),May cause seizures in patients with history of epilepsy,Not recommended for chemotherapy-induced nausea in patients receiving concomitant central nervous system depressants
Central nervous system depression (drowsiness, dizziness, ataxia),Psychiatric effects (euphoria, dysphoria, paranoia, hallucinations),Cognitive and motor impairment (do not drive or operate machinery),Risk of dependence and withdrawal syndrome,Use with caution in patients with history of psychiatric disorders,May increase heart rate and blood pressure
Hypersensitivity to dronabinol or any component of the formulation,History of hypersensitivity to marijuana or cannabinoids,Breastfeeding (due to potential infant exposure)
Hypersensitivity to nabilone or any cannabinoid,History of seizure disorder,Breastfeeding (excreted in milk)
High-fat meals may increase absorption; take consistently with respect to meals. Avoid grapefruit juice as it may increase dronabinol levels.
Take with food or milk to reduce gastrointestinal upset; avoid grapefruit juice as it may alter drug metabolism.
Dronabinol is a synthetic cannabinoid. Data on human pregnancy are limited. Animal studies show developmental toxicity at high doses. First trimester: potential risk of fetal abnormalities cannot be excluded; avoid unless benefit outweighs risk. Second and third trimesters: may cause fetal neurobehavioral effects; use only if clearly needed. Late pregnancy: associated with neonatal withdrawal symptoms and possible long-term neurodevelopmental effects.
Nabilone (Cesamet) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects including skeletal anomalies at doses 0.2-2 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may increase risk of congenital malformations. Second and third trimester exposure may affect fetal growth and neurobehavioral development. Potential risks include low birth weight, preterm birth, and neonatal withdrawal symptoms.
Dronabinol is excreted into breast milk. The milk-to-plasma ratio (M/P) is not established but cannabinoids are highly lipophilic and concentrate in milk. Effects on the nursing infant are unknown; however, potential for adverse effects on neurodevelopment exists. Breastfeeding is not recommended during dronabinol therapy.
Nabilone is excreted into breast milk; a specific M/P ratio is not reported. Due to the high lipid solubility and long half-life, significant infant exposure is expected. Breastfeeding is contraindicated due to potential adverse effects on infant neurodevelopment and cannabinoid receptor activation.
Pregnancy may alter dronabinol pharmacokinetics (increased volume of distribution, altered hepatic metabolism), but specific dose adjustments are not established. Use the lowest effective dose for the shortest duration. Monitor for increased adverse effects from altered metabolism. Avoid use in pregnancy unless potential benefit justifies potential risk to the fetus.
Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced hepatic metabolism) may reduce nabilone serum concentrations, potentially requiring dose adjustments. However, due to lack of safety data, use during pregnancy is not recommended. If deemed essential, the lowest effective dose should be used, and close monitoring for efficacy and toxicity is advised.
Dronabinol is synthetic THC, used for chemotherapy-induced nausea and vomiting (CINV) and appetite stimulation in AIDS wasting. Onset is 0.5-1 hour orally; titrate slowly due to psychoactive effects. May cause euphoria, dizziness, and cognitive impairment. Use with caution in patients with psychiatric disorders, seizure disorders, or history of substance abuse. Monitor for hypotension and tachycardia. Avoid concurrent use with other CNS depressants.
Titrate slowly to reduce risk of syncope and orthostatic hypotension; monitor for dizziness and sedation; may cause euphoria or dysphoria; use with caution in patients with history of psychiatric disorders; taper to discontinue.
Take exactly as prescribed; do not increase dose or frequency.,Avoid driving or operating heavy machinery until you know how this medication affects you.,This drug may cause dizziness, drowsiness, or confusion; avoid alcohol and other CNS depressants.,Report any mood changes, hallucinations, or unusual thoughts to your healthcare provider.,Keep out of reach of children and store in a cool, dry place.,For nausea, take at least 1 hour before chemotherapy (if used as prophylaxis).,For appetite stimulation, take before meals.
Avoid driving or operating machinery until you know how this drug affects you.,Get up slowly from sitting or lying down to prevent dizziness or fainting.,Avoid alcohol and other sedatives while taking this medication.,Take exactly as prescribed; do not increase dose without consulting your doctor.,Store at room temperature away from moisture and heat.
"Ethotoin, a hydantoin anticonvulsant, potentiates the central nervous system (CNS) depressant effects of dronabinol, a cannabinoid used for nausea and appetite stimulation. This additive CNS depression can lead to excessive sedation, dizziness, ataxia, and impaired cognitive and motor function. Clinically, patients may experience increased risk of falls, respiratory depression at high doses, and reduced ability to perform tasks requiring alertness."
"Nabilone, a synthetic cannabinoid agonist, and dronabinol, a synthetic delta-9-tetrahydrocannabinol, both exert central nervous system (CNS) depressant effects via activation of cannabinoid receptors (CB1) in the brain. Concurrent use leads to additive or synergistic CNS depression, resulting in enhanced sedation, dizziness, ataxia, and impairment of cognitive and motor function. Clinically, this may manifest as excessive drowsiness, confusion, or impaired coordination, increasing the risk of falls or accidents, especially in elderly or debilitated patients."
"Thiothixene, a typical antipsychotic with significant antidopaminergic and alpha-adrenergic blocking properties, may potentiate the central nervous system (CNS) depressant effects of dronabinol, a cannabinoid used for appetite stimulation and antiemesis. This additive CNS depression can lead to excessive sedation, dizziness, psychomotor impairment, and increased risk of falls or cognitive dysfunction. Clinically, patients may experience heightened somnolence, ataxia, or orthostatic hypotension, particularly during initiation or dose titration of either agent."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DRONABINOL vs CESAMET, answered by our medical review team.
DRONABINOL is a Cannabinoid that works by Partial agonist at cannabinoid receptors CB1 and CB2; mimics endogenous cannabinoids, inhibiting adenylate cyclase and modulating neurotransmitter release (e.g., GABA, glutamate).. CESAMET is a Antiemetic (cannabinoid) that works by Nabilone is a synthetic cannabinoid (CB1 receptor agonist) with antiemetic and anxiolytic effects. It binds to central cannabinoid receptors (CB1) in the brain, inhibiting neurotransmitter release and modulating emetic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DRONABINOL and CESAMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DRONABINOL is: 2.5-10 mg orally twice daily, titrated to effect; maximum 15 mg per day in divided doses.. The standard adult dose of CESAMET is: 1-2 mg orally twice daily; maximum 6 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DRONABINOL and CESAMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DRONABINOL is classified as Category D/X. Dronabinol is a synthetic cannabinoid. Data on human pregnancy are limited. Animal studies show developmental toxicity at high doses. First trimester: potential risk of fetal abnor. CESAMET is classified as Category C. Nabilone (Cesamet) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects including skeletal anomalies at doses 0.2-2 times the maximum recommende. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.